In conclusion, our retrospective analysis of 21 patients with the ABC subtype of DLBCL showed that 33% of patients treated with R-CHOP either progressed or relapsed, whereas none of the patients treated with DA-REPOCH progressed or relapsed. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.